# US 5,344,829 A · Use of OB-101 to treat inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,344,829 A
- Document ID: US5344829A
- Status: Granted
- Kind: A
- Application number: 08/103,255
- Filed: 1993-08-06
- Granted: 1994-09-06
- Earliest claimed: 1991-12-03
- Assignees: The Texas A&M University System
- Inventors: George C. Y. Chiou
- Web page: https://patentgrep.com/patent/US5344829A

## CPC

- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel compound for the treatment and prevention of ocular and other types of inflammation is disclosed. The compound, OB-101, is effective at both the early and late phases of inflammation. The compound is useful for the treatment of inflammation in both the anterior and posterior portions of the eye, as well as in other parts of the body.

## Claims

### Claim 1

A method for the treatment and prevention of inflammation in an animal subject which method comprises administering to said subject an inflammation-controlling effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable vehicle in admixture with a compound having the formula ##STR4##

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound is administered orally.

### Claim 3 (depends on 1)

The method of claim 1 wherein the compound is administered parenterally.

### Claim 4 (depends on 1)

The method of claim 1 wherein the compound is administered topically.

### Claim 5 (depends on 1)

The method of claim 1 wherein the inflammation is selected from the group consisting of arthritis, inflammatory bowel disease and pulmonary inflammation.